During acute human immunodeficiency virus type 1 (HIV-1) infection or after transfection of the tat gene, Tat protein is released into the cell culture supernatant. In this extracellular form, Tat stimulates both HIV-1 gene expression and the growth of cells derived from Kaposi's sarcoma (KS) lesions of HIV-1-infected individuals (AIDS-KS cells). Tat protein and its biological activities appear in the cell supernatants at the peak of Tat expression, when the rate of cell death is low (infection) or cell death is undetectable (transfection) and increased levels of cytoplasmic Tat are present. Tat-containing supernatants stimulate maximal AIDS-KS cell growth but only low to moderate levels of HIV-1 gene expression. This is due to the different concentrations of exogenous Tat required for the two effects. The cell growth-promoting effects of Tat peak at between 0.1 and 1 ng of purified recombinant protein per ml in the cell growth medium and do not increase with concentration. In contrast, both the detection of nuclear-localized Tat taken up by cells and the induction of HIV-1 gene expression or replication require higher Tat concentrations (>100 ng/ml), and all increase linearly with increasing amounts of the exogenous protein. These data suggest that Tat can be released by a mechanism(s) other than cell death and that the cell growth-promoting activity and the virus-transactivating effect of extracellular Tat are mediated by different pathways.
Human immunodeficiency virus type 1 (HIV-1) is the causal agent of AIDS (5, 22, 32, 39) . The infection is characterized by immune dysfunction, opportunistic infections, and frequent occurrences of proliferative diseases, particularly Kaposi's sarcoma (KS) (21, 30) . HIV-1 possesses several regulatory genes, among which tat encodes an early protein (Tat) that transactivates HIV-1 gene expression through interaction with the Tat activation response (TAR) element of the HIV-1 long terminal repeat (LTR). This is essential for viral replication (1, 6, 10, 17, 18, 27, 28, 40, 41, 43, 50) . We and others have previously shown that Tat possesses other activities. During acute infection of T cells by HIV-1, Tat is released into the cell culture supernatant (14) . In this extracellular form, Tat stimulates the growth of spindle cells of vascular origin derived from KS lesions of patients with AIDS (AIDS-KS cells) and that of normal vascular cells which have been exposed to inflammatory cytokines (3, 14, 36) . These results, and data showing that tat-transgenic mice develop dermal lesions resembling KS (49) , have suggested that Tat plays a role in the pathogenesis of AIDS-associated KS (13) . Previous data also indicated that extracellular Tat protein can be taken up by cultured cell lines, can be localized into the nuclei, and can transactivate HIV-1 LTR-directed gene expression (3, 6, 19, 20, 23) . Transcellular transactivation by Tat has also been observed by coculturing cells containing the HIV-1 promoter with a Tat-expressing cell line (29) .
Similar activities have recently been reported for the human T-cell leukemia-lymphoma virus type I (HTLV-I) transactivator protein, Tax (33, 35, 47) , indicating that 278 ENSOLI ET AL. described in the legend to Fig. 1 24) as described previously (14) and utilized for HIV-1 transactivation assays (see below). For the coculture experiments, infected and uninfected cells were cocultured with COS-1 cells transfected with the HIV-1 LTR-chloramphenicol acetyltransferase (CAT) plasmids, as described in footnote a of Table 1 .
Plasmid DNA and transfection into COS-1 cells. Wild-type tat-expressing vectors (CMV-TAT and PCV-TAT), the construct CMV-M-TAT containing a mutation in the basic region of Tat (Arg-52 to Leu), and the control vector DNAs (CMV-0 and PCV-0) have all been previously described (14, 45) . The HIV-1 LTR-CAT construct (CD23-CAT) and its mutant (ABS-CAT), with a deletion of 4 nucleotides in the TAR region, have also been previously described (15 (42) .
CM from cells transfected with Tat-expressing plasmids or control vectors were prepared as described previously (14) .
Tat protein and anti-Tat antibodies. The Tat protein used in these studies was expressed in Eschenchia coli and isolated by successive rounds of high-pressure liquid chromatography and ion-exchange chromatography. Analysis of purified protein was by silver staining (Bio-Rad) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and indicated the protein to be >95% pure (6 (3, 6, 14) .
Rabbit polyclonal and mouse monoclonal anti-Tat antibodies were both raised against recombinant purified Tat protein expressed in E. coli, affinity purified with immobilized purified Tat protein, and analyzed by Western blotting (immunoblotting) and radioimmunoprecipitation analysis (RIPA) on Tat-transfected cells and Tat-expressing cell lines (3, 6, 14) .
RIPA of Tat. HIV-1-infected and uninfected H9 cells (106/ml) and COS-1-transfected cells were metabolically labeled for 24 and 6 to 8 h, respectively, with both [35S]methionine and cysteine (150 ,uCi/ml each). Supernatants (3 to 4 ml) and cell extracts (500 ,ul) were prepared and used for immunoprecipitation analysis with the polyclonal anti-Tat antibodies (1:100) as previously described (14) .
Immunostaining (19, 20, 23) . Twelve to 16 h later, cell extracts were prepared and used for CAT assays by overnight incubation (3, 15, 26 (3, 14, 16, 37, 38, 46) . Tat buffer, medium alone, and the control CM were used as negative controls.
The inhibition of Tat-induced cell growth was performed by preincubating Tat or Tat-containing supernatants at 40C for 6 to 12 h with serial dilutions of the anti-Tat polyclonal antibodies (14) . Cell proliferation was then measured by cell counting and/or thymidine incorporation. Controls for specificity and toxicity were performed by adding the antibodies to Tat buffer, control CM, or the known growth inducers of AIDS-KS cells (HTLV-II CM or bFGF) as described previously (3, 14) .
Cellular uptake of Tat. AIDS-KS cells were plated on glass slides (8 wells per slide). After 24 to 48 h, cells were washed and incubated for 1 h in serum-free medium. Serial dilutions of Tat (0.01, 0.1, 1, or 10 ,ug/ml) were then added to the cells, which were incubated either at 37 or at 4°C for 15, 30, 60, and 180 min. Cells were then washed with PBS, fixed in acetone and chloroform (1:1), and stained with the anti-Tat monoclonal antibodies as described above. Blocking of Tat uptake was performed by preincubating the protein for 1 to 2 h (4°C) with antibody prior to adding it to the cells. Each experiment was performed in duplicate. The procedure for the negative control was the same, except that Tat buffer was used.
Rescue of Tat-defective provirus by Tat. The HeLa-CD4-expressing cell line containing an integrated, nonrevertant, Tat-defective HIV-1 provirus (HLM1 cell line) (44) (14) and that exogenous Tat protein transactivates HIV-1 gene expression (3, 6, 19, 20, 23) . In order to determine whether during acute HIV-1 infection released Tat was able to transactivate HIV-1 gene expression in a paracrine fashion, CM from H9-infected T cells (H9-HIV CM) or from uninfected cells (H9 CM) from sequential time points postinfection were assayed for transactivating activity by scrape loading into COS-1 cells transfected with the HIV-1 LTR-CAT construct (3, 6) . H9-HIV CM stimulated low levels of HIV-1 LTR-directed gene expression compared with those by purified Tat protein used as a positive control and with those by CM from uninfected control cells (onefold). Transactivation was transient and concordant with the presence of immunoreactive Tat in the cell supernatants ( Fig. 1A and B) . To verify whether the activation of HIV gene expression by CM was due to the presence of Tat in the CM, H9-HIV CM was scrape loaded into cells transfected with a deletion mutant of the Tatresponsive region (TAR) of the HIV-1 LTR (ABS-CAT) (15) (Fig. 1C) . This mutant is not responsive to Tat but is still responsive to TAR-independent inducers of the HIV-1 LTR (3, 15) . The transactivating effect of CM was markedly reduced (Fig. 1C) , confirming that it was largely mediated by Tat. Similar results were obtained with Jurkat cells (data not shown).
In these experiments, however, HIV-1 transactivation was observed by utilizing the scrape-loading procedure. This allows the entry of exogenous proteins into cells by the avoidance of cell membrane-protein interactions (20, 23 (14) . To correlate this observation with the HIV-1 transactivation ability of extracellular Tat, CM from cells transfected with tat (PCV-TAT) or the control vector (PCV-0) were utilized in cell growth experiments with AIDS-KS cells and in transactivation assays by the scrapeloading procedure (Fig. 3) . The Tat-containing CM induced maximal AIDS-KS cell proliferation when compared with that by known inducers of AIDS-KS cell growth (CM from HTLV-II-infected cells and bFGF) (3, 14, 16, 37, 38, 46) (Fig. 3A, left panel) . Cell growth was inhibited by preincubating the CM with anti-Tat antibodies, while the antibodies had no effect on the cell growth induced by the HTLV-II CM (Fig. 3A, right panel) (14) . In contrast, only modest levels of HIV-1 LTR-directed gene expression were observed after the Tat-containing CM were scrape loaded into COS-LTRtransfected cells, compared with the levels with CM from cells transfected with the vector DNA (PCV-0) (Fig. 3B) .
Transactivation was reduced after the Tat-containing CM were scrape loaded into cells transfected with the ABS-CAT construct (Fig. 3C) Table 2 , and some examples are shown in Fig. 4 and 5.
AIDS-KS cell growth assays with CM from transfected cells). The results from these experiments are summarized in
The percentage of Tat-positive cells and total Tat content (intracellular and extracellular) were higher in PCV-TATtransfected cells and lower in cells transfected with the CMV-M-TAT construct than in CMV-TAT-transfected cells ( Fig. 4 and 5 ; Table 2 ). In all cases, the protein was detected in both the nuclei and the cytoplasm of the cells. However, cytoplasmic Tat was present in a larger fraction of cells transfected with PCV-TAT and was detected predominantly in the cytoplasm of CMV-M-TAT-transfected cells ( Fig. 4 ; Table 2 ). The fraction of Tat released by the cells correlated with the level of total Tat content (higher in PCV-TATtransfected cells) and with the levels of cytoplasmic Tat (prevalent in PCV-TAT-and CMV-M-TAT-transfected cells) ( Fig. 5; Table 2 ). Interestingly, cells transfected with CMV-M-TAT released levels of Tat similar to those released by cells transfected with CMV-TAT, although the total Tat content and the percentage of Tat-positive cells were lower (Fig. SB) . This results in a proportionally higher fraction of protein released into the cell supernatants (Table 2 ). In agreement with these data, intracellular Tat activity was lower for the CMV-M-TAT construct than for its wild-type plasmid (CMV-TAT), while extracellular Tat activity was about the same for CMV-M-TAT and CMV-TAT ( only low to moderate levels of HIV-1 transactivation. This suggested that cell growth requires a lower concentration of extracellular Tat than the transactivating effect. To verify this, serial dilutions of recombinant-purified Tat protein were added to AIDS-KS cells, and cell growth was monitored by both cell counting (Fig. 6A, left panel) and [3H]thymidine incorporation (Fig. 6B) . Tat stimulated cell growth at concentrations of 0.05 to 50 ng/ml, with peak activity at between 0.1 and 1 ng/ml (Fig. 6) . No growth stimulation was observed with concentrations of Tat at 100 ng/ml or higher (Fig. 6) . The cell proliferation stimulated by Tat was at the maximal inducible level compared with that by known growth simulators of AIDS-KS cells, such as HTLV-II CM and bFGF (Fig. 6) (3, 13, 14, 16, 36-38, 46) . Preincubation of Tat with the anti-Tat antibodies abolished the growth response promoted by Tat, yet it had no effect on cell growth stimulated by other growth inducers (HTLV-II CM) or on the basal level of cell growth (Fig. 6A, right panel) , confirming the specificity and the lack of toxicity of the antibodies (3, 14) . Similar results were recently obtained with normal vascular endothelial and smooth-muscle cells, potential progenitors of AIDS-KS cells, which proliferate in response to Tat after being exposed to cytokines from activated T cells (3) . These results indicate that only picomolar amounts, or less, of extracellular Tat are required to stimulate cell growth. The same Tat preparations were then used in assays of viral transactivation and replication ( Fig. 7 and 8) .
With COS cells transiently transfected with the HIV-1 LTR, detectable levels of gene expression were obtained by the direct addition of concentrations of Tat greater than 500 ng/ml (Fig. 7A) or by scrape loading of the protein (100 ng/ml) into the cells (Fig. 7B) . Similar Tat concentrations were required to induce viral replication by adding or scrape loading Tat into HeLa-CD4-expressing cells containing a nonreversible, Tat-defective HIV-1 provirus (HLM1 cell line) (44) (Fig. 8) . In both systems, transactivation increased linearly with Tat concentrations when either procedure, direct addition or scrape loading, was employed. These results are in agreement with previous data (17, 19, 20, 23, 34) and indicate that the concentrations of exogenous Tat required to activate HIV-1 gene expression and replication are higher than those needed for the cell growth effect. In addition, the kinetics of dose-response to Tat differ for the two types of effects.
Uptake and nuclear localization of Tat by AIDS-KS cells require protein concentrations similar to those necessary for HIV-1 transactivation. To transactivate the HIV-1 LTR, extracellular Tat must be taken up by cells and be localized into the nuclei (19, 20, 23, 34) . As AIDS-KS cells cannot be transfected at the efficiency required for gene expression studies, the direct comparison of the Tat concentrations required for cell growth with those required for transactivation could not be made for the same cell type. However, as nuclear localization of Tat is required for transactivation (28, 43, 45) , this was monitored after the addition of exogenous Tat to AIDS-KS cells. Cells were incubated with serial dilutions of Tat (from 0.01 to 10 ,ug/ml) for different periods (from 15 min to 3 h) and then stained with the affinity-purified anti-Tat monoclonal antibodies by the double indirect immunoperoxidase procedure (Fig. 9 ). Uptake and nuclear localization of Tat were clearly and consistently detectable only by incubating the cells with 100 ng of the protein per ml or more. These (particularly the nucleolar localization) increased by increasing the concentration of exogenous Tat or the time of incubation of the cells with the protein. An example of the nuclear uptake of Tat after incubation of the cells with 1 ,ug or 100 ng of the protein per ml is shown in Fig.   9 . Staining was abolished when Tat was preincubated with the anti-Tat antibodies (Fig. 9B) . Similar to the results of previous experiments (34), the cellular uptake of Tat was reduced (low-level and diffuse cytoplasmic staining only) by incubations being performed at 4°C instead of at 37°C (data not shown). The results indicate that the concentrations of extracellular Tat required for nuclear-nucleolar localization of the protein are higher than needed for the cell growth effect and are much closer to those necessary for viral transactivation or replication. As for transactivation, the nuclear uptake of Tat is concentration and time dependent, increasing linearly with both, in agreement with previous data (19, 20, 23, 34) . Table 2 (3, 14, 16, 37, 38) , and medium alone or protein buffer was used as a negative control. To verify specificity and lack of toxicity, the antibodies were also added to HTLV-II CM or to the medium alone, as previously described (14) . In both types of assays, AIDS-KS cell growth was monitored by a cell-counting method and expressed as a multiple of the number of cells plated (onefold tion and viral replication, particularly after the direct addition of the protein (.500 ng/ml). Viral transactivation by extracellular Tat increases linearly with increasing amounts of exogenous protein (19, 20, 23, 34) , while the cell growth effect peaks at between 0.1 and 1 ng of Tat per ml and is not observed at concentrations higher than 50 to 100 ng/ml.
As AIDS-KS cells cannot be transfected at the efficiency required for transactivation studies, HIV-1 gene expression and cell growth could not be monitored by using the same cell type. However, uptake and nuclear localization of Tat are required for transactivation; thus, we studied this requirement by incubating AIDS-KS cells with concentrations of Tat that induced cell growth or viral transactivation (Fig.   9 ). Nuclear localization of Tat was observed at Tat concentrations similar to those needed for transactivating effects, confirming the previous data of others (34) . As with transactivation, uptake and nuclear localization of Tat are dose dependent, increasing with concentration, and are dependent on the time of incubation of the cells with the protein.
These data confirm that cell growth requires a lower concentration of extracellular Tat than does the transactivating effect.
The data presented here suggest that different pathways mediate the cell growth-promoting effect and the uptaketransactivation effect of extracellular Tat (3, 4) . This is in agreement with previous data (12, 31, 51) and suggests that an inducible Tat receptor(s) mediates the cell growth-promoting effect of the protein.
